- Septa Pharmaceuticals has acquired CeeNU (lomustine) from Bristol Myers Squibb Canada, effective June 29, 2026, expanding its specialty pharmaceutical portfolio into critical care and oncology.
- CeeNU is an established alkylating chemotherapy agent primarily used in the treatment of certain brain tumors and Hodgkin’s lymphoma.
- Septa said it is prioritizing the continued availability and uninterrupted supply of CeeNU for Canadian patients and healthcare professionals during the transition.
- The acquisition supports Septa’s broader expansion strategy as the company continues to pursue strategic partnerships, licensing opportunities, and global commercialization of high-impact therapies.
Takeaways:
Septa’s acquisition of CeeNU from Bristol Myers Squibb turns it into a supply‑critical oncology player in Canada, securing an essential chemotherapy that has faced shortage risk and reinforcing its positioning in brain tumors and Hodgkin’s lymphoma while creating a platform to in‑license more divested or distressed oncology brands as part of its global expansion strategy.
Source: PRnewswire
